1. Home
  2. DQ vs ANIP Comparison

DQ vs ANIP Comparison

Compare DQ & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DAQO New Energy Corp.

DQ

DAQO New Energy Corp.

HOLD

Current Price

$20.84

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$74.63

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DQ
ANIP
Founded
2006
2001
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2010
1999

Fundamental Metrics

Financial Performance
Metric
DQ
ANIP
Price
$20.84
$74.63
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$28.91
$110.00
AVG Volume (30 Days)
595.1K
296.8K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
419.23
EPS
N/A
3.32
Revenue
N/A
$206,547,000.00
Revenue This Year
$70.27
$23.05
Revenue Next Year
$34.95
$14.08
P/E Ratio
N/A
$22.87
Revenue Growth
N/A
2.47
52 Week Low
$12.41
$56.71
52 Week High
$36.59
$99.50

Technical Indicators

Market Signals
Indicator
DQ
ANIP
Relative Strength Index (RSI) 37.93 48.91
Support Level $20.47 $72.43
Resistance Level $25.90 $77.47
Average True Range (ATR) 0.91 2.07
MACD 0.02 0.41
Stochastic Oscillator 15.49 57.59

Price Performance

Historical Comparison
DQ
ANIP

About DQ DAQO New Energy Corp.

Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: